Skip to content
Lysosomal Disease Network
  • Home
  • News
  • Events
  • Research
  • Resources
  • About
  • Submit
  • Opportunities

covid-19 disruptions

Invisible burden of COVID-19: enzyme replacement therapy disruptions

Posted on April 7, 2021

Scheduled enzyme replacement therapy (ERT) during COVID-19 has often been disrupted. This article considers the possibility of adverse outcomes caused by the disruption in the treatment of patients with lysosomal storage disorders. The full text of the article is available here.

Posted in Research | Tagged covid-19 disruptions, enzyme replacement therapy covid-19, ert disruption

Recent Posts

  • Lysosomal Disease Network annual meeting 2022
  • Precision Metrics for Cognition
  • Protected: NIH Mucopolysaccharidosis Fact Sheet
  • Passing of Patient/Advocate Erica Thiel
  • Watch this space for a future announcement of the Lysosomal Disease Network Annual Meeting, a virtual research meeting to be scheduled for Spring, 2022

Contact Information

Lysosomal Disease Network
420 Delaware Street SE
MMC 446
Minneapolis, MN 55455
info@nulllysosomaldiseasenetwork.org

Chester B. Whitley, PhD, MD
Principal Investigator,
Lysosomal Disease Network
Professor, Dept. of Pediatrics
University of Minnesota,
Twin Cities

David CC Erickson
Informatics Director,
Webmaster
Lysosomal Disease Network

James C. Cloyd, PharmD
Co-Principal Investigator,
Lysosomal Disease Network

Brenda Diethelm-Okita, MPA
Program Manager,
Lysosomal Disease Network

Additional Info

  • Patient Organizations
  • Official List of Lysosomal Diseases
  • Submit Content to LDN
  • Sign up for PubMed Updates
  • LDN Fellowships
  • Submit RFA for Pilot Project
  • Lysosomal Disease Network Fellows
  • Contact LDN
  • Opportunities
  • Opportunities

Recent Posts

  • Lysosomal Disease Network annual meeting 2022
  • Precision Metrics for Cognition
  • Protected: NIH Mucopolysaccharidosis Fact Sheet
  • Passing of Patient/Advocate Erica Thiel
  • Watch this space for a future announcement of the Lysosomal Disease Network Annual Meeting, a virtual research meeting to be scheduled for Spring, 2022
RDCRN Logo
The Lysosomal Disease Network (U54NS065768) is a part of the National Institutes of Health (NIH) Rare Diseases Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
© 2022 Lysosomal Disease Network